The chapter

Engineering longer healthspan hinges on making tissue repair and systemic maintenance controllable, with the main bottlenecks being safe whole-body delivery, validated measures of aging and repair, and long-duration governance of powerful interventions. As of 2026, real-world impact still mostly comes from risk-factor control and disease prevention, while somatic gene therapy has reached regulated clinical use, including the first FDA-approved hemophilia gene therapy reported in 2023. CRISPR is advancing under tightening regulatory scrutiny amid complex IP. Practical priorities are scalable, tissue-selective delivery (often nanoparticles), robust tissue-expression baselines (e.g., GTEx), and selecting high-burden conditions as early healthspan ROI targets.

This record lists the chapter's canonical sources and its revisions as recorded on Comuvia's BookWriter and MediaManager systems. The chapter and its video are AI-authored and AI-produced; the sources ground the text, they do not endorse it.

Chapter 78. Longevity, Regeneration, and Engineered Health — chapter poster

Sources

The chapter's canonical source pack as recorded on BookWriter: milestone papers, patents and news found through Crossref, OpenAlex, USPTO and news providers. Tier reflects citation strength, not Comuvia's endorsement.

#TypeSourceTierFound via
1PaperThe CRISPR Patent Ruling and Implications for Medicine
Paradise, Jordan · JAMA · 2023 · doi:10.1001/jama.2022.24986
gold · highly citedcrossref
2PaperDaily briefing: CRISPR patent ruling won’t be the end of it
Graham, Flora · Nature · 2022 · doi:10.1038/d41586-022-00721-3
gold · highly citedcrossref
3PaperFirst FDA-Approved Gene Therapy for Hemophilia
Larkin, Howard · JAMA · 2023 · doi:10.1001/jama.2022.23510
gold · highly citedcrossref
4PaperDaily briefing: Safety review is big step towards the first FDA-approved CRISPR therapy
Graham, Flora · Nature · 2023 · doi:10.1038/d41586-023-03409-4
gold · highly citedcrossref
5PaperEngineering precision nanoparticles for drug delivery
Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley et al. · 2020 · doi:10.1038/s41573-020-0090-8
gold · highly citedopenalex
7,125 citations
6PaperNatural products in drug discovery: advances and opportunities
Atanas G. Atanasov, Sergey B. Zotchev, Verena M. Dirsch et al. · 2021 · doi:10.1038/s41573-020-00114-z
gold · highly citedopenalex
4,811 citations
7PaperGut microbiota in human metabolic health and disease
Yong Fan, Oluf Pedersen · 2020 · doi:10.1038/s41579-020-0433-9
gold · highly citedopenalex
4,421 citations
8PaperIn silico analysis enabling informed design for genome editing in medicinal cannabis; gene families and variant characterisation
Matchett-Oates, Lennon, Braich, Shivraj, Spangenberg, German et al. · 2019 · doi:10.26181/6153922fe919c
gold · highly citedopenalex
4,235 citations
9PaperA framework for advancing our understanding of cancer-associated fibroblasts
Erik Sahai, Igor Astsaturov, Edna Cukierman et al. · 2020 · doi:10.1038/s41568-019-0238-1
gold · highly citedopenalex
3,682 citations
10PaperGlobal, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · 2017 · doi:10.1016/s0140-6736(17)32154-2
gold · highly citedopenalex
13,473 citations
11PaperThe Genotype-Tissue Expression (GTEx) project.
John T. Lonsdale · 2013 · doi:10.1038/ng.2653
gold · highly citedopenalex
9,907 citations
12PaperNano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto et al. · 2018 · doi:10.1186/s12951-018-0392-8
gold · highly citedopenalex
6,407 citations

Revisions

WhenEventDetail
May 6, 2026Source pack versionversion 4 · refresh coverage gap · 12 entries
May 6, 2026Source checkpass · coverage 100 %
Aug 29, 2026Upload (full)uploaded · Ilv748CRkwo
Aug 29, 2026Upload (short_15s)uploaded · giGSlsZQPPY
Sep 2, 2026Published on the channelupload date as listed on the channel · SbB3ZhX7N_U

About this record

Book: The Long Horizon: A Vision of Frontier Technology from 2026 to 2400 (BookWriter (Comuvia S2)). Channel: Comuvia Vision. Sources are the chapter's canonical source pack in BookWriter (milestone papers, patents and news found through Crossref, OpenAlex, USPTO and news providers; tiers gold/strong by citation strength); revisions are the pack versions, the compliance checks and the campaign's uploads. The chapter text itself is AI-authored on BookWriter; the sources ground it, they do not endorse it.

anchor 86a27ab1-5cb8-4bf8-b5b2-f61bb6998566 · thread c5a53ff3-994d-4653-879c-9bf2fb0a0a29